[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628760":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":29,"locations":35,"responsibleParty":80,"collaborators":28,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":28,"eligibilityCriteria":87,"healthyVolunteers":84,"sex":88,"minAge":89,"maxAge":28,"enrollmentInfo":90,"targetDuration":28,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":38,"whyStopped":28,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Electra Therapeutics Inc.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Level 0 Arm","EXPERIMENTAL","Starting dose level",[13],"Drug: ELA026",{"label":15,"type":10,"description":16,"interventionNames":17},"Level -1 Arm","Dose level below Starting Dose Level",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Level +1 Arm","Dose level above Starting Dose Level",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","ELA026","Weekly maintenance dosing via subcutaneous injection",[19,15,9],null,[30],{"name":31,"role":32,"phone":33,"phoneExt":28,"email":34},"Clinical Trials Electra Clinical Trials Information","CONTACT","Please email","clinicaltrials@electra-therapeutics.com",[36,50,60,70],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":28},"Yale New Haven Hospital","RECRUITING","New Haven","Connecticut","06520","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-72.92816,41.30815,{"lat":48,"lon":47},{"facility":51,"status":38,"city":52,"state":53,"zip":54,"country":42,"countryCode":43,"cosmosGeoPoint":55,"geoPoint":59,"contacts":28},"Emory University Hospital","Atlanta","Georgia","30322",{"type":45,"coordinates":56},[57,58],-84.38798,33.749,{"lat":58,"lon":57},{"facility":61,"status":38,"city":62,"state":63,"zip":64,"country":42,"countryCode":43,"cosmosGeoPoint":65,"geoPoint":69,"contacts":28},"START, Midwest","Grand Rapids","Michigan","49546",{"type":45,"coordinates":66},[67,68],-85.66809,42.96336,{"lat":68,"lon":67},{"facility":71,"status":38,"city":72,"state":73,"zip":74,"country":42,"countryCode":43,"cosmosGeoPoint":75,"geoPoint":79,"contacts":28},"University Hospitals Cleveland Medical Center","Cleveland","Ohio","44106",{"type":45,"coordinates":76},[77,78],-81.69541,41.4995,{"lat":78,"lon":77},{"type":81,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100628760","phase-1-a-study-of-ela026-in-participants-with-relapsedrefractory-rr-tnk-cell-malignancies-tcms-100628760",false,"NCT07465835","A Study of ELA026 in Participants With Relapsed\u002FRefractory (R\u002FR) T\u002FNK Cell Malignancies (TCMs)","Inclusion Criteria:\n\n* Age ≥18 years Participants with a confirmed histologic diagnosis of a TCM who are R\u002FR following any line of prior therapy (participants with CTCLs should have received at least 2 prior lines of systemic therapy for R\u002FR CTCL) and eligible for investigational therapies\n* Presence of measurable disease by clinical examination, radiologic imaging (computed tomography, magnetic resonance imaging, or whole body FDG-PET scans), and\u002For in bone marrow aspirate\u002Fbiopsy\n* Eastern Cooperative Oncology Group performance score of ≤2\n* Anticipated life expectancy \\>6 months per investigator judgment\n\nExclusion Criteria:\n\n* Participants who are eligible for standard of care or approved therapeutic options for R\u002FR TCMs with established clinical benefit\n* Organ dysfunction as defined in the protocol\n* Participants with hemophagocytic lymphohistiocytosis (HLH) based on HLH2004 diagnostic criteria\n* Participants receiving or planning to start immunotherapy or immune effector cell therapy (such as chimeric antigen receptor \\[CAR\\] T-cell therapy, T-cell engagers, or programmed cell death protein 1 \\[PD1\\]\u002Fprogrammed cell death ligand 1 \\[PD-L1\\] inhibitors)\n* Allogeneic hemopoietic stem cell transplant within 100 days prior to the first dose of ELA026 and currently receiving systemic immunosuppressive therapy\n* Women of childbearing potential who are planning to become pregnant or are breastfeeding during the conduct of the study, including 60 days after last dose of study drug\n* Male participants whose partners are women of childbearing potential and who are planning to become pregnant during the conduct of this trial by the male partner, including within 60 days after the last dose of study drug","ALL","18 Years",{"count":91,"type":92},84,"ESTIMATED","INTERVENTIONAL",[95],"PHASE1","This is a Phase 1, two-part, multicenter study to evaluate ELA026 in participants ≥18 years old with relapsed\u002Frefractory TCM following any line of prior therapy who are eligible for investigational treatments.",[98],"T Cell Malignancies",[100,101,102,25],"T cell Malignancies","Lymphoma","SIRP protein","2026-05-17",{"date":105,"type":106},"2026-05-20","ACTUAL",{"date":108,"type":106},"2026-02-17",{"date":110,"type":92},"2028-12",{"name":5,"class":6},4]